Overview
The marketing authorisation for Zalviso has been withdrawn at the request of the marketing authorisation holder.
Zalviso : EPAR - Summary for the public
English (EN) (663.58 KB - PDF)
български (BG) (760.64 KB - PDF)
español (ES) (667.71 KB - PDF)
čeština (CS) (739.15 KB - PDF)
dansk (DA) (665.9 KB - PDF)
Deutsch (DE) (670.41 KB - PDF)
eesti keel (ET) (665.35 KB - PDF)
ελληνικά (EL) (762.93 KB - PDF)
français (FR) (669.36 KB - PDF)
hrvatski (HR) (686.42 KB - PDF)
italiano (IT) (666.44 KB - PDF)
latviešu valoda (LV) (738.28 KB - PDF)
lietuvių kalba (LT) (688.61 KB - PDF)
magyar (HU) (733.2 KB - PDF)
Malti (MT) (741.01 KB - PDF)
Nederlands (NL) (667.09 KB - PDF)
polski (PL) (738.41 KB - PDF)
português (PT) (668.03 KB - PDF)
română (RO) (688.79 KB - PDF)
slovenčina (SK) (737.52 KB - PDF)
slovenščina (SL) (730.65 KB - PDF)
Suomi (FI) (665.44 KB - PDF)
svenska (SV) (667.37 KB - PDF)
Zalviso : EPAR - Risk-management-plan summary
English (EN) (656.57 KB - PDF)
Product information
Zalviso : EPAR - Product Information
English (EN) (1.16 MB - PDF)
български (BG) (2.02 MB - PDF)
español (ES) (1.14 MB - PDF)
čeština (CS) (1.73 MB - PDF)
dansk (DA) (1.14 MB - PDF)
Deutsch (DE) (1.08 MB - PDF)
eesti keel (ET) (1.15 MB - PDF)
ελληνικά (EL) (2.07 MB - PDF)
français (FR) (1.17 MB - PDF)
hrvatski (HR) (1.23 MB - PDF)
íslenska (IS) (1.11 MB - PDF)
italiano (IT) (1.08 MB - PDF)
latviešu valoda (LV) (3.17 MB - PDF)
lietuvių kalba (LT) (1.21 MB - PDF)
magyar (HU) (1.8 MB - PDF)
Malti (MT) (1.81 MB - PDF)
Nederlands (NL) (1.13 MB - PDF)
norsk (NO) (1.14 MB - PDF)
polski (PL) (1.77 MB - PDF)
português (PT) (1.14 MB - PDF)
română (RO) (1.24 MB - PDF)
slovenčina (SK) (1.72 MB - PDF)
slovenščina (SL) (1.74 MB - PDF)
Suomi (FI) (1.05 MB - PDF)
svenska (SV) (1.14 MB - PDF)
Latest procedure affecting product information: T/0017
05/08/2022
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zalviso : EPAR - All Authorised presentations
English (EN) (590.39 KB - PDF)
български (BG) (630.83 KB - PDF)
español (ES) (589.36 KB - PDF)
čeština (CS) (612.66 KB - PDF)
dansk (DA) (588.95 KB - PDF)
Deutsch (DE) (588.89 KB - PDF)
eesti keel (ET) (588.92 KB - PDF)
ελληνικά (EL) (629.13 KB - PDF)
français (FR) (589.08 KB - PDF)
hrvatski (HR) (600.21 KB - PDF)
íslenska (IS) (588.96 KB - PDF)
italiano (IT) (589.31 KB - PDF)
latviešu valoda (LV) (622.41 KB - PDF)
lietuvių kalba (LT) (605.38 KB - PDF)
magyar (HU) (618.12 KB - PDF)
Malti (MT) (620.25 KB - PDF)
Nederlands (NL) (589.22 KB - PDF)
norsk (NO) (589.15 KB - PDF)
polski (PL) (620.57 KB - PDF)
português (PT) (589.37 KB - PDF)
română (RO) (606.42 KB - PDF)
slovenčina (SK) (619.68 KB - PDF)
slovenščina (SL) (618.15 KB - PDF)
Suomi (FI) (589.19 KB - PDF)
svenska (SV) (589.02 KB - PDF)
Product details
- Name of medicine
- Zalviso
- Active substance
- sufentanil
- International non-proprietary name (INN) or common name
- sufentanil
- Therapeutic area (MeSH)
- Pain, Postoperative
- Anatomical therapeutic chemical (ATC) code
- N01AH03
Pharmacotherapeutic group
AnestheticsTherapeutic indication
Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.
Authorisation details
- EMA product number
- EMEA/H/C/002784
- Marketing authorisation holder
- FGK Representative Service GmbH
Heimeranstrasse 35
80338 Munich
Germany - Opinion adopted
- 23/07/2015
- Marketing authorisation issued
- 18/09/2015
- Revision
- 7
Assessment history
Zalviso : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (706.73 KB - PDF)
Zalviso-H-C-PSUSA-00002798-201811 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
English (EN) (657.2 KB - PDF)
Zalviso : EPAR - Public assessment report
English (EN) (4.53 MB - PDF)
CHMP summary of positive opinion for Zalviso
English (EN) (642.12 KB - PDF)
News on Zalviso
More information on Zalviso
Public statement on Zalviso : Withdrawal of the marketing authorisation in the European Union
English (EN) (124.46 KB - PDF)